Adverse effects of modified release oxycodone/naloxone in patients with moderate to severe liver impairment

Venessa Pattullo, Gavin G Pattullo and Simone I Strasser
Med J Aust 2018; 209 (6): . || doi: 10.5694/mja18.00380
Published online: 17 September 2018

To the Editor:

  • 1 Royal North Shore Hospital, Sydney, NSW
  • 2 University of Sydney, Sydney, NSW
  • 3 AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, NSW

Competing interests:

No relevant disclosures.

  • 1. TGA eBusiness Services. Product Information TARGIN modified release tablets. Sydney: Mundipharma; 2017. (viewed Mar 2018).
  • 2. Franklin AE, Lovell MR, Boyle F. A case of opioid toxicity on conversion from extended-release oxycodone and naloxone to extended-release oxycodone in a patient with liver dysfunction. J Pain Symptom Manage 2017; 53: e1-e2.
  • 3. Lau F, Gardiner M. Oxycodone/naloxone: an unusual adverse drug reaction. Aust Fam Physician 2017; 46: 42-43.
  • 4. Smith K, Hopp M, Mundin G, et al. Low absolute bioavailability of oral naloxone in healthy subjects. Int J Clin Pharmacol Ther 2012; 50: 360-367.
  • 5. Tovoli F, De Lorenzo S, Samolsky Dekel BG, et al. Oral oxycodone/naloxone for pain control in cirrhosis: observational study in patients with symptomatic metastatic hepatocellular carcinoma. Liver Int 2018; 38: 278-284.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.